CTOs on the Move

BioDigital

www.biodigital.com

 
BioDigital is a New York-based biomedical visualization company that is often referred to as being "Google Earth for the Human Body".
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Mike Robinson
VP of Engineering Profile

Similar Companies

BlossomHill Therapeutics

BlossomHill Therapeutics is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Dallas Employment Services

Dallas Employment Services , Inc. is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Predictive Biosciences

Predictive Biosciences is an innovative developer of molecular diagnostic tests for cancer diagnosis and monitoring. We are focused on understanding and meeting the needs of physicians by providing valuable diagnostic services and laboratory solutions.

CareDx

CareDx: Transforming Transplant Patient Care Through Novel Surveillance Management Solutions CareDx, Inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. By combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, CareDx is at the forefront of organ transplant surveillance and pre-transplant HLA typing solutions.

Regado Biosciences

Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.